IMC-X5: Neuromuscular Blocking Agent Activity and Safety Data

18 compounds were studied in a structure-activity relationship analysis to optimize an imidazolium-based neuromuscular blocking agent. The monofluorinated macrocycle IMC-X5 demonstrated a 47% faster onset, 34% longer profound blockade, and 89% shorter recovery time compared to the lead compound IMC-0 in rat model tests at a 0.2 mg/kg dose. The dataset, shared by Shi-Xian Gan in May 2026, likely contains the experimental results supporting these findings.

Use Cases

• Comparing blockade onset and duration profiles based on chemical halogenation
• Analyzing biosafety improvements for novel neuromuscular blocking agents
• Modeling structure-activity relationships for imidazolium-based macrocycles
• Evaluating the reversal efficacy of acyclic cucurbit[n]uril antagonists

Strengths

• Includes data from a structure-activity relationship study of 18 distinct compounds
• Reports specific percentage improvements (e.g., 47% faster onset) from in vivo rat model tests
• Contains results for a promising drug candidate (IMC-X5) and its lead compound (IMC-0)

Limitations

• Row count is unknown, which may limit suitability assessment
• Column-level documentation is absent; field semantics must be inferred after download
• Data scale is limited to 3.1 KB, suggesting a small, focused dataset

Provenance

Source

figshare

Collection Method

Likely contains experimental results from chemical synthesis and in vivo rat model testing.

Freshness

Last updated 2026-05-29 09:45:27; freshness should be verified